Sector: Health Care
Director information for TREVI THERAPEUTICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Anne VanLent | President | 78 | ["President of AMV Advisors","Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc.","Member of the board of directors and audit committee chair of ObsEva SA","Member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation","B.A. in physics from Mount Holyoke College","Financial and accounting expertise"] | [] | 2026 |
| David Hastings | Chief Financial Officer | 64 | ["Chief Financial Officer at Arbutus Biopharma Corporation","Chief Financial Officer at Unilife Corporation","Chief Financial Officer and Executive Vice President at Incyte Corporation","Chief Financial Officer and Treasurer of ArQule Inc.","various management positions at Genzyme Inc.","Director of Finance at Sepracor Inc.","Senior Manager at Coopers & Lybrand"] | ["audit committee"] | 2026 |
| David Meeker, M.D. | Chairman of the Board | 71 | ["President and Chief Executive Officer of Rhythm Pharmaceuticals","Chief Executive Officer and director of KSQ Therapeutics","President and Chief Executive Officer of Genzyme","medical director at Genzyme Corporation","director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic","Assistant Professor of Medicine at Ohio State University"] | [] | 2026 |
| Dominick Colangelo | President and Chief Executive Officer | 62 | ["More than 20 years of executive management and corporate development experience in the biopharmaceutical industry","Experience with Eli Lilly and Company","Held various executive positions in product development, pharmaceutical operations, sales and marketing, and corporate development","Extensive experience in the acquisition, development, and commercialization of products across therapeutic areas","B.S.B.A. in Accounting from the State University of New York at Buffalo","J.D. from Duke University School of Law"] | [] | 2026 |
| Edward Mathers | Director | 66 | ["Partner at New Enterprise Associates, Inc.","Director of multiple publicly traded biopharmaceutical companies","Experience investing in and advising life sciences companies","Director of public and private companies in the life sciences industry","B.S. in chemistry from North Carolina State University"] | [] | 2026 |
| Farrell Simon, Pharm. D. | Chief Commercial Officer | 44 | ["Chief Commercial Officer","Senior Vice President, Head of Commercial and Strategy","Vice President, Head of US Marketing","Senior Director, Chief of Staff to the Biopharma Group President at Pfizer Inc.","Founder and Chief Executive Officer of The Simon Cancer Foundation","Experience at Procter & Gamble","M.B.A. from the University of Florida","Pharm.D. from the University of Florida"] | [] | 2026 |
| James Cassella, Ph.D. | Chief Development Officer | 71 | ["Ph.D. in Physiological Psychology from Dartmouth College","Postdoctoral fellowship in Psychiatry at Yale University School of Medicine","B.A. in Psychology from the University of New Haven","Chief Development Officer experience at Sun Pharmaceutical Industries Inc.","Chief Development Officer experience at Concert Pharmaceuticals, Inc.","Executive Vice President, Research and Development and Chief Scientific Officer at Alexza Pharmaceuticals, Inc.","Various management positions at Neurogen Corporation"] | [] | 2026 |
| Jennifer Good | President and Chief Executive Officer | 61 | ["Co-founder","President and Chief Executive Officer since 2011","Various positions at Penwest Pharmaceuticals Co. from 1997 to 2010","Bachelor of Business Administration with a concentration in accounting","Certified Public Accountant"] | [] | 2026 |
| Michael Heffernan | Lead Independent Director | 61 | ["Founder of Collegium Pharmaceutical","Chairman of the Board of Collegium from July 2018 to May 2025","Interim President and Chief Executive Officer of Collegium from May 2024 until November 2024","President, Chief Executive Officer and a director of Collegium from October 2002 until July 2018","Co-founded Avenge Bio and served as Chairman since 2019","Chief Executive Officer of Avenge Bio from January 2022 until May 2024","Advisor, investor and board member of biopharmaceutical, medical device and healthcare services companies","Chairman of the Board of Avalo Therapeutics since March 2025","Board member of enGene Holdings Inc. since July 2025","Chairman of the Board of Par Health since November 2025","Board member of Biohaven LTD since January 2020","Served on the board of directors of Synlogic, Inc. and Akebia Therapeutics, Inc.","Over 30 years of experience in the life sciences industry"] | [] | 2026 |
| Thomas Sciascia, M.D. | Chief Scientific Officer | 72 | ["Co-founder","Chief Medical Officer from inception until November 2022","Senior Vice President of Clinical Development and Regulatory at Penwest","Board-certified neurologist","B.S. in biology from MIT","Medical degree from Columbia University"] | [] | 2026 |
